AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes ...

The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

AstraZeneca's AZD0780 has demonstrated significant efficacy in a Phase IIb trial, showing a 50.7% reduction in LDL-C after 12 ...

AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of ...

AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes for a potential blockbuster that could be part of a powerful combination ...

WILMINGTON, Del. - AstraZeneca (AZN), a prominent player in the global pharmaceuticals industry with a market capitalization of $225 billion, has shown promising results with its experimental drug ...

AstraZeneca has revealed phase 2b results with its oral PCSK9 inhibitor AZD0780, including a more than 50% reduction in ...